CoChat
Sign Up
Cited by 460Rheumatoid Arthritis Research and TherapiesImmunodeficiency and Autoimmune DisordersT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

Bingham, Clifton O., Looney, R. John, Deodhar, Atul, Halsey, Neal, Greenwald, Maria, Codding, Christine, Trzaskoma, Benjamin, Martin, Flavius, Agarwal, Sunil, Kelman, Ariella·2010·Arthritis & Rheumatism
DOI 10.1002/art.25034
Open this paper in CoChat — free account

Abstract

Objective: To examine immunization responses in patients with rheumatoid arthritis (RA) treated with rituximab and to investigate the effects of rituximab‐induced CD20+ B cell depletion on immune responses to tetanus toxoid (T cell–dependent antigen), pneumococcal polysaccharide (T cell–independent antigen), and keyhole limpet hemocyanin (KLH) (neoantigen) and on delayed‐type hypersensitivity (DTH). Methods: In a controlled trial, we enrolled 103 patients with active RA receiving a stable dose of methotrexate (MTX). Tetanus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test were administered to 1 group of patients receiving rituximab plus MTX (called rituximab‐treated patients) for 36 weeks and to 1 group of patients receiving MTX alone for 12 weeks. The primary end point was the proportion of patients with a ≥4‐fold rise in antitetanus IgG levels. Antitetanus, antipneumococcal, and anti‐KLH serum IgG levels were measured prior to and 4 weeks following vaccine administration. The DTH response to C albicans was measured 2–3 days following placement. Results: Responses to tetanus toxoid vaccine (≥4‐fold rise) were similar in both groups (39.1% of rituximab‐treated patients and 42.3% of patients treated with MTX alone). The ability to maintain a positive DTH response to the C albicans skin test was comparable in both groups (77.4% of rituximab‐treated patients and 70% of patients treated with MTX alone), showing no effect of rituximab treatment. Rituximab‐treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had a 2‐fold rise in titer in response to ≥1 serotype, compared with 82% of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti‐KLH IgG, compared with 93% of patients treated with MTX alone). Conclusion: Recall responses to the T cell–dependent protein antigen tetanus toxoid as well as DTH responses were preserved in rituximab‐treated RA patients 24 weeks after treatment. Responses to neoantigen (KLH) and T cell–independent responses to pneumococcal vaccine were decreased, but many patients were able to mount responses. These data suggest that polysaccharide and primary immunizations should be administered prior to rituximab infusions to maximize responses.

Overview

Integrity signals

Registry

Crossref · 10.1002/art.25034

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. 2008, Pneumovax package insert
  2. Galazka A, The Immunological Basis for Immunization Series Module 3: Tetanus
  3. Handwerger B, 2004, Effects of Anakinra (KINERET) on vaccine response in patients with rheumatoid arthritis, Arthritis Rheum, 50, S564

Cited by

Sorted by citations

Items 401–460 of 460

Related

See all

Metadata

Authors
Bingham, C. O., Looney, R. J., Deodhar, A., Halsey, N., Greenwald, M., Codding, C., Trzaskoma, B., Martin, F., Agarwal, S., & Kelman, A.
Affiliations
  • Johns Hopkins University (US)
  • University of Rochester (US)
  • Oregon Health & Science University (US)
  • Genentech (US)
ORCID
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-12-28
Volume
62
Issue
1
Pages
64-74
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/art.25034
OpenAlex
W2042927558
Cited by
459
References
37
Citations by year
2026: 12 · 2025: 14 · 2024: 15 · 2023: 27 · 2022: 33 · 2021: 64 · 2020: 33 · 2019: 23 · 2018: 22 · 2017: 35 · 2016: 21 · 2015: 29 · 2014: 28 · 2013: 34 · 2012: 23
FWCI
16.04
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Arthritis & Rheumatism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
rheumatoid arthritis, rituximab, immunization response, vaccine immunogenicity, tetanus toxoid vaccine, pneumococcal polysaccharide vaccine, keyhole limpet hemocyanin, delayed-type hypersensitivity, methotrexate, T cell-independent response
MeSH terms
Rituximab, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antibody Formation, Arthritis, Rheumatoid, Drug Therapy, Combination, Female, Hemocyanins, Humans, Hypersensitivity, Delayed, Immunologic Memory, Influenza Vaccines, Lymphocyte Depletion, Male, Methotrexate, Middle Aged, Skin Tests, Tetanus Toxoid, Vaccines, B-Lymphocyte Subsets, Antirheumatic Agents, Lymphocyte Count, Antigens, CD20, Pneumococcal Vaccines, Young Adult, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review